Correlation of Epstein–Barr virus (EBV) expressed miRNAs (BART4, BART7, and BHRF1) with chronic lymphocytic leukemia stages
- 1Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
- 2Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
- 3Department of Medical Virology, Faculty of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract
Background: Epstein-Barr virus (EBV) has been shown to play a role in the pathogenesis of several B-cell malignancies, but its role in chronic lymphocytic leukemia (CLL) remains unclear. EBV-encoded microRNAs, including BHRF1 and BART families, are thought to modulate host cell survival and apoptosis. This study aimed to evaluate the expression of EBV miRNAs in CLL patients and assess their association with disease stage and viral load.
Methods: In this study, peripheral blood mononuclear cells (PBMCs) were separated using the Ficoll-Paque density gradient method from 20 EBV-positive CLL patients, including early-stage (stage 0–1, n = 10) and advanced-stage (stage 3–4, n = 10) groups. EBV viral load was quantified using real-time PCR targeting EBNA-1, and expression levels of BHRF1, BART4, and BART7 miRNAs were measured using stem-loop RT-qPCR. Correlations between miRNA expression, viral load, and clinical stage were analyzed.
Results: EBV viral load was significantly higher in advanced-stage CLL patients than in early-stage patients (P = 0.0363). However, miR-BHRF1 expression tended to be higher in early-stage patients than in advanced-stage patients; however, this difference was not statistically significant (P > 0.05). In contrast, miR-BART4 and miR-BART7 were significantly upregulated in advanced-stage patients (P < 0.05). Notably, BHRF1 expression positively correlated with EBV DNA load (r = 0.516, p = 0.019), while no significant association was observed for BART4 (p = 0.174, r = 0.316) or BART7 (p = 0.117, r = 0.361).
Conclusion: Our results indicate that EBV-encoded miRNAs exhibit differential expression in CLL depending on disease stage and may contribute to leukemic progression. BHRF1, in particular, may serve as a biomarker of viral activity and early-stage disease, while BART miRNAs may promote advanced-stage pathogenesis. Further studies are warranted to validate these miRNAs as potential prognostic markers and therapeutic targets in CLL.
Related
- False-negative HHV-8 immunohistochemistry in Kaposi sarcoma: Clinicopathologic correlation leading to diagnosis of occult chronic lymphocytic leukemia
- A Rare Case of Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia in an Elderly Patient: A Case Report
- An Atypical Presentation of Richter's Transformation in Chronic Lymphocytic Leukemia: Stroke-Like Onset With Multiorgan Involvement Including the Heart and Seminal Vesicles
- [Chronic lymphocytic leukemia presenting initially as purpura nephritis: a case report].
- Comment on "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation".
BibTeX
@article{keyvanlou2026correlation,
title = {{Correlation of Epstein–Barr virus (EBV) expressed miRNAs (BART4, BART7, and BHRF1) with chronic lymphocytic leukemia stages}},
author = {Zahra Keyvanlou and Mehrdad Ravanshad and Saeid Amel Jamehdar and Elham Babaei},
journal = {Infectious Agents and Cancer},
year = {2026},
month = jul,
doi = {10.1186/s13027-026-00785-0},
url = {https://doi.org/10.1186/s13027-026-00785-0},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Correlation of Epstein–Barr virus (EBV) expressed miRNAs (BART4, BART7, and BHRF1) with chronic lymphocytic leukemia stages
AU - Zahra Keyvanlou
AU - Mehrdad Ravanshad
AU - Saeid Amel Jamehdar
AU - Elham Babaei
PY - 2026
DA - 2026/07/31
JO - Infectious Agents and Cancer
DO - 10.1186/s13027-026-00785-0
UR - https://doi.org/10.1186/s13027-026-00785-0
AB - Background: Epstein-Barr virus (EBV) has been shown to play a role in the pathogenesis of several B-cell malignancies, but its role in chronic lymphocytic leukemia (CLL) remains unclear. EBV-encoded microRNAs, including BHRF1 and BART families, are thought to modulate host cell survival and apoptosis. This study aimed to evaluate the expression of EBV miRNAs in CLL patients and assess their association with disease stage and viral load. Methods: In this study, peripheral blood mononuclear cells (PBMCs) were separated using the Ficoll-Paque density gradient method from 20 EBV-positive CLL patients, including early-stage (stage 0–1, n = 10) and advanced-stage (stage 3–4, n = 10) groups. EBV viral load was quantified using real-time PCR targeting EBNA-1, and expression levels of BHRF1, BART4, and BART7 miRNAs were measured using stem-loop RT-qPCR. Correlations between miRNA expression, viral load, and clinical stage were analyzed. Results: EBV viral load was significantly higher in advanced-stage CLL patients than in early-stage patients (P = 0.0363). However, miR-BHRF1 expression tended to be higher in early-stage patients than in advanced-stage patients; however, this difference was not statistically significant (P > 0.05). In contrast, miR-BART4 and miR-BART7 were significantly upregulated in advanced-stage patients (P < 0.05). Notably, BHRF1 expression positively correlated with EBV DNA load (r = 0.516, p = 0.019), while no significant association was observed for BART4 (p = 0.174, r = 0.316) or BART7 (p = 0.117, r = 0.361). Conclusion: Our results indicate that EBV-encoded miRNAs exhibit differential expression in CLL depending on disease stage and may contribute to leukemic progression. BHRF1, in particular, may serve as a biomarker of viral activity and early-stage disease, while BART miRNAs may promote advanced-stage pathogenesis. Further studies are warranted to validate these miRNAs as potential prognostic markers and therapeutic targets in CLL.
SN - 1750-9378
ER -